These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9142801)
1. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Brown BA; Griffith DE; Girard W; Levin J; Wallace RJ Clin Infect Dis; 1997 May; 24(5):958-64. PubMed ID: 9142801 [TBL] [Abstract][Full Text] [Related]
2. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932 [TBL] [Abstract][Full Text] [Related]
3. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. Jeong BH; Jeon K; Park HY; Moon SM; Kim SY; Lee SY; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2016 Oct; 60(10):6076-83. PubMed ID: 27480854 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Dunne M; Fessel J; Kumar P; Dickenson G; Keiser P; Boulos M; Mogyros M; White AC; Cahn P; O'Connor M; Lewi D; Green S; Tilles J; Hicks C; Bissett J; Schneider MM; Benner R Clin Infect Dis; 2000 Nov; 31(5):1245-52. PubMed ID: 11073759 [TBL] [Abstract][Full Text] [Related]
5. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. Deshpande D; Pasipanodya JG; Gumbo T Antimicrob Agents Chemother; 2016 Apr; 60(4):2157-63. PubMed ID: 26810646 [TBL] [Abstract][Full Text] [Related]
6. Resumption/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen. Kobayashi T; Tsuyuguchi K; Yoshida S; Kimura Y; Tsuji T; Minomo S; Kurahara Y; Inoue Y; Suzuki K Respir Investig; 2021 Mar; 59(2):212-217. PubMed ID: 33436352 [TBL] [Abstract][Full Text] [Related]
7. Two faces of MAC-induced lung disease. Tetenta S; Abunasser J; Bandyopadhyay T Conn Med; 2008 Apr; 72(4):203-5. PubMed ID: 18478985 [TBL] [Abstract][Full Text] [Related]
8. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Griffith DE; Brown BA; Girard WM; Wallace RJ Clin Infect Dis; 1995 Sep; 21(3):594-8. PubMed ID: 8527549 [TBL] [Abstract][Full Text] [Related]
9. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. Griffith DE; Brown BA; Murphy DT; Girard WM; Couch L; Wallace RJ J Infect Dis; 1998 Jul; 178(1):121-6. PubMed ID: 9652431 [TBL] [Abstract][Full Text] [Related]
10. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969 [TBL] [Abstract][Full Text] [Related]
11. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520 [TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719 [TBL] [Abstract][Full Text] [Related]
14. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931 [TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice. Bermudez LE; Petrofsky M; Inderlied CB; Young LS J Antimicrob Chemother; 1995 Oct; 36(4):641-6. PubMed ID: 8591938 [TBL] [Abstract][Full Text] [Related]
17. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Wallace RJ; Brown BA; Griffith DE; Girard WM; Murphy DT Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1766-72. PubMed ID: 8665032 [TBL] [Abstract][Full Text] [Related]